28 May 2026
Swissmedic: Federal contribution to the Swiss Agency for Therapeutic Products Swissmedic to be increased
At its meeting on 27 May 2026, the Federal Council approved a CHF 2.7 million increase in the federal contribution to the Swiss Agency for Therapeutic Products Swissmedic for 2027. The Federal Council has made the increase contingent on the full implementation of the measures approved by the Agency Council last November to improve results. At the same time, the Federal Council approved the revision of the Swissmedic Fees Ordinance. This includes the introduction of a registration fee for medical devices.
For more information, see here
More News
-
-
Swissmedic: New strategic Approach to minimizing Animal Testing in the Development of Medicinal Products
-
Swissmedic: The new Pharmacopoea Helvetica 13
-
European Medicines Agency: New oral GLP-1 Medicine for Weight Management and Type 2 Diabetes
-
FOPH: Capital Income of Health Insurers for Premium Reduction – current voluntary System deemed sufficient
-
Swissmedic: Haemovigilance Annual Report 2025
-
Decision C-6534/2024 of 13 October 2026
-
Swissmedic: GMP Compliance by foreign Manufacturers - Simplifications for Industry and Clarification of unresolved Issues
-
European Medicines Agency: Clinical Trial Applications Advice Pilot becomes permanent
-
European Medicines Agency: Highlights of the September 2026 Management Board meeting